Skip to main navigation

albireo_logo_nav.svg

  • About
    • Overview
    • Enterprise Team
    • Board of Directors
    • Partnering
    • Contact
  • Programs & Science
    • Bile Acids and IBAT Inhibition
    • Pipeline
    • Odevixibat
    • A3384
    • Elobixibat
  • Patients & Families
    • Progressive Familial Intrahepatic Cholestasis (PFIC)
    • ALAGILLE SYNDROME
    • BILIARY ATRESIA
    • Chronic (Idiopathic) Constipation
    • ADULT LIVER DISEASES
    • Bile Acid Malabsorption (BAM)
    • Clinical Trials
    • Expanded Use
  • Media & Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Publications
    • 2020 Annual Meeting
    • Corporate Governance
    • Stock Information
    • Financials & Filings
    • Analyst Coverage
    • Contact Us
  • Careers
    • Current Openings

Albireo Provides Third Quarter 2020 Business Update

Financials menu

  • Financials & Filings

Stock Information menu

  • Stock Information

governance menu

  • Corporate Governance

Albireo Provides Third Quarter 2020 Business Update

Nov 17, 2020 at 10:00 AM EST

Listen to webcast

Supporting Materials

View Presentation 1.9 MB

Shareholder Tools

  • Email Alerts

    Email Alerts

  • RSS

    RSS

  • Print

    Print

 
albireo-white

© 2018 Albireo Pharma, Inc.

Contact |  Terms of Use  |  Privacy Policy      twitter